Spectral AI to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
2023年9月21日 - 5:15AM
Spectral AI, Inc.
(Nasdaq: MDAI; MDAIW) (“Spectral AI” or the
“Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, announced today that the Company
will present at the 2023 Cantor Fitzgerald Global Healthcare
Conference taking place September 26-28, 2023 in New York City. The
Company will also host 1x1 meetings during the event.
Details of the Company's participation are as follows:
- Format: Fireside Chat with Wensheng Fan, Chief
Executive Officer
- Date: Wednesday, September 27, 2023
- Time: 4:10 pm
ET
Interested parties may access the live webcast
of the fireside chat by visiting the Investors section of Spectral
AI’s website at
https://investors.spectral-ai.com/news-events/events.
Company Highlights
- Spectral AI’s
internally developed DeepView® System integrates proprietary
optical technology with AI-enabled algorithms to provide clinicians
with a healing potential assessment in seconds by clearly defining
healing versus non-healing tissue invisible to the naked eye.
- Spectral AI’s
artificial intelligence models are trained and tested against a
growing, proprietary and clinically validated database of over 263
billion data points only available to DeepView users and developed
over more than eight years of clinical studies across the U.S. and
Europe.
- Spectral AI is
building on $130+ million to date of non-dilutive U.S. Government
contracts for burn wound healing assessment, including under the
U.S. federal mass casualty countermeasures program, and is
expanding its AI technology platform into Diabetic Foot Ulcers and
multiple other clinical indications.
About Spectral AISpectral AI is
a predictive AI company focused on medical diagnostics for faster
and more accurate treatment decisions in wound care for burn, DFU,
and future clinical applications. At Spectral AI, we are a
dedicated team of forward-thinkers striving to revolutionize the
management of wound care by “Seeing the Unknown”® with our
DeepView® Wound Diagnostics System. The Company’s DeepView®
platform is a predictive diagnostic device that offers clinicians
an objective and immediate assessment of a wound’s healing
potential prior to treatment or other medical intervention. With
algorithm-driven results that have a goal of substantially
exceeding the current standard of care in the future, Spectral MD’s
diagnostic platform is expected to provide faster and more accurate
treatment insight and improve patient care while reducing
healthcare costs. For more information, visit the Company at:
www.spectral-ai.com
Forward Looking Statements
Certain statements made in this release are “forward looking
statements” within the meaning of the “safe harbor” provisions of
the United States Private Securities Litigation Reform Act of 1995,
including statements regarding the Company’s strategy, plans,
objectives, initiatives and financial outlook. When used in this
press release, the words “estimates,” “projected,” “expects,”
“anticipates,” “forecasts,” “plans,” “intends,” “believes,”
“seeks,” “may,” “will,” “should,” “future,” “propose” and
variations of these words or similar expressions (or the negative
versions of such words or expressions) are intended to identify
forward-looking statements.
These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
Company’s control, that could cause actual results or outcomes to
differ materially from those discussed in the forward-looking
statements. As such, readers are cautioned not to place undue
reliance on any forward-looking statements.
Investors should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” sections of the Company’s filings with the
SEC, including the Registration Statement and the other documents
filed by the Company. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements.
ContactSpectral AI, Ltd.
ir@spectral-ai.comChristine Marks, VP of Marketing
and Commercializationmarks@spectralmd.com
Investors:The Equity
GroupDevin SullivanManaging
Directordsullivan@equityny.com
Conor RodriguezAnalystcrodriguez@equityny.com
Media:Russo PartnersDavid
Schull or Guillermo Ruiz, M.D., Ph.D.Russo Partners(858)
717-2310david.schull@russopartnersllc.com
Guillermo Ruiz, M.D., Ph.D.Russo Partners(858)
717-2310Guillermo.ruiz@russopartnersllc.com
Spectral AI (NASDAQ:MDAI)
過去 株価チャート
から 5 2024 まで 6 2024
Spectral AI (NASDAQ:MDAI)
過去 株価チャート
から 6 2023 まで 6 2024